Objective: We investigated the clinical significance of ERp57 in the progression of cervical cancer. Methods: mRNA and protein expression of ERp57 in cervical neoplasias were examined. Results: ERp57 mRNA expression was significantly decreased in cervical cancers. Immunohistochemistry revealed that ERp57 expression in 123 cervical cancers was down-regulated compared to cervical intraepithelial neoplasias or normal tissues (p<0.001). Low ERp57 expression was significantly associated with worse overall survival (HR=12.19, p=0.018). Conclusions: Low ERp57 expression independently predicts a poor outcome for patients with cervical cancer, supporting the notion that ERp57 may be a promising novel cancer target.
Bibliographical noteFunding Information:
This work was supported in part by grants from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0005230, 2011-0010286, and 2011-0007146), and faculty research grants from Yonsei University College of Medicine for 2010 and 2011 (3-2010-0072 and 6-2011-0073).
After gaining institutional review board approval, 123 paraffin-embedded cervical cancer, 187 cervical intraepithelial neoplasia (CIN) and 310 matched normal cervix tissues that had been resected at Gangnam Severance Hospital, Yonsei University College of Medicine between 1996 and 2010 were retrieved. Some of the paraffin blocks were provided by the Korea Gynecologic Cancer Bank through the Bio & Medical Technology Development Program of the Korea Ministry of Education, Science and Technology. All tumor tissues were histologically revised and only specimens with sufficient tumor cells were included in the tissue microarray (TMA) construction. Tumor staging was performed according to the International Federation of Gynecology and Obstetrics (FIGO) classification system.
All Science Journal Classification (ASJC) codes
- Clinical Biochemistry
- Health, Toxicology and Mutagenesis